Customer Advisory Board
Meet leaders from our customer community who are strategically working with us to identify emerging trends and inform our roadmap to help move research forward.
Dr. Howard H. Bailey, M.D.
Director and Professor of Medicine, University of Wisconsin Carbone Cancer Center
Dr. Howard H. Bailey, M.D. is the Andy and Susan North Professor of Cancer Research, Professor of Medicine and Obstetrics & Gynecology and Director of the University of Wisconsin Carbone Cancer Center (UWCCC). The UWCCC was one of the original National Cancer Institute-designated comprehensive cancer centers and is currently one of approximately 40 comprehensive cancer centers in the U.S. Dr. Bailey, a medical oncologist who has specialized in the development of new anti-cancer agents for prevention or therapy, currently lead a group of NCI-designated cancer centers in the development of novel cancer prevention agents. He recently was the Chair of the Cancer Prevention Committee of the American Society of Clinical Oncology which is the largest professional society in the world focused on cancer care and research. In that role he authored an international position paper on the need for increased HPV vaccination rates in the U.S. and around the globe.
William K. Barnett, Ph.D.
Director of Information Infrastructures, Indiana
William K. Barnett, Ph.D. is the Chief Research Informatics Officer (CRIO) for the Indiana Clinical and Translational Sciences Institute (CTSI) and the Regenstrief Institute. In that role, he has a dual integrated mission. First, to provide, integrate, and advance biomedical informatics services, particularly the development of informatics infrastructures for precision health and other advanced research applications, and to lead the research data and analytics services. In that he provides strategic leadership for applied informatics for the Indiana CTSI and Regenstrief. Second, to engage in informatics research to develop and apply innovative approaches to advancing healthcare research as a Regenstrief Investigator. His current focus is on secondary use of medical records, precision health informatics, and team science at national scales. He is infrastructure lead for the Indiana University Precision Health Initiative, and is a Associate Research Professor in the Department of Medical and Molecular Genetics at the IU School of Medicine.
Teri A. Grieb, Ph.D
Senior Director of Research, Michigan
Teri Grieb, Ph.D., is the Chief of Staff, Research Enterprise for Michigan Medicine and Senior Director for Research at the University of Michigan Medical School. In these roles, she partners with Michigan Medicine’s Chief Scientific Officer and the Medical School Senior Associate Dean for Research in advocacy for the research mission.
As the chief business and administrative officer for the research mission, Dr. Grieb is responsible for the operational and fiscal management of the Medical School Office of Research and its reporting units. She assists with developing and implementing strategic initiatives, leading enterprise change management, fostering collaborations with the research community across the university, and advising on policy, procedural, and operational issues for the research enterprise. Dr. Grieb serves as the lead administrative liaison and primary staff interface between the Medical School research enterprise and the institution.
Dr. Grieb holds a Ph.D. from the Genetics Program at George Washington University. After receiving her doctorate, she joined an early-stage, life sciences company, where she was the Director of Tissue Biologics and lead scientist responsible for developing the company’s licensed technology for sterilizing allograft tissues. Dr. Grieb then joined MedImmune, Inc., as a R&D project manager. She oversaw commercial and university in-licensed technologies. Prior to her current roles at the University of Michigan, Dr. Grieb was the Industry Research Liaison and was responsible for planning and implementing outreach activities to increase participation in technology transfer, grow partnerships with industry, and foster entrepreneurship.
Deputy Director, Chief Operating Officer, YCCI; Associate Director for Clinical Research for Yale School of Medicine
Tesheia Johnson, MBA, MHS, is Deputy Director and Chief Operating Officer of YCCI and the Associate Director for Clinical Research for Yale School of Medicine, where she provides leadership and direction in clinical research. Her career has focused on the development of clinical research programs and support infrastructure. Prior to assuming her current position, she held positions as Assistant Dean for Clinical Research at the University of Vermont College of Medicine and Director of Clinical Trials at the University of Wisconsin-Madison. She has served as a consultant for several academic centers interested in establishing clinical research programs and as a grant reviewer for the National Institutes of Health.
Ms. Johnson is nationally recognized for her expertise in the design and setup of clinical research programs. She has been an invited speaker at many national and international conferences on topics such as developing funding for central support for clinical research, staffing models for clinical and translational research, training programs for research professionals, clinical research regulation, and contracting and budget negotiation. She has served as Chair and co-Chair for several National Clinical and Translational Science Award (CTSA) Consortium Group/Committees. She sits on the external scientific advisory boards for the CTSAs at NYU, Washington University, Rockefeller, and the Universities of Washington, Florida, and Buffalo.
Dr. Arash Naeim, M.D., Ph.D.
Chief Medical Officer for Clinical Research; Assistant Vice Chancellor for Research; Associate Director, Clinical Translational Science Institute; Co-Director, UCLA Center for SMART Health
Dr. Arash Naeim, M.D., Ph.D. is a Professor of Medicine in both Divisions of Hematology-Oncology and Geriatric Medicine at the David Geffen UCLA School of Medicine. He is Associate Director for the Clinical Translational Science Institute, and Chief Medical Officer for Clinical Research for the UCLA Campus and Health System. His research interests included outcomes research, cost-effectiveness analysis, modeling of health and frailty, and clinical trial design. His focus of research for the majority of his publications and research grants has been in breast cancer and cancer in the elderly. He is the UCLA Principal Investigator for the Athena Breast Health Network and NIH grant that aims to use sensor technology and analytics to reduce risk, integrate innovative technology, and advance precision medicine.
Dr. Naeim is very involved in information technology implementation and research. He is a board certified Clinical Informaticist for the UCLA Health System, Director of Informatics for the Jonsson Comprehensive Cancer Center, and led the UCLA Campus strategic planning effort for Research Informatics on behalf of the Vice Chancellor of Research. He has implemented numerous systems on behalf of the Cancer Center and Health System. He also directs the Clinical Research Information Systems Office and the Embedded Clinical Research and Innovation Unit. He has recently expanded his involvement in health and innovation by serving as Co-Director for the Center for SMART Health, a joint center between the David Geffen School of Medicine and the School of Engineering and Applied Science.
Denise Clutter Snyder, M.S., R.D., L.D.N.
Associate Dean for Clinical Research, Duke University of Medicine
Denise received her BS (’93) and MS (’97) degrees in Nutrition at Penn State University. After relocating to North Carolina in 1997, she worked in public health and clinical nutrition, but soon gravitated back to research work at Duke as a project manager in 2000 where she managed several NIH/NCI-funded protocols involving an array of diet and exercise interventions with breast, prostate and colorectal cancer survivors. She has co-authored more than 50 publications and presented at national conferences. In 2008, Denise used her research and Duke-specific experience to create the Research Management Team (RMT) to support the School of Nursing’s research faculty. In 2009, RMT received support from Duke’s CTSA to leverage the group’s services for the School of Medicine and became the home for the REDCap implementation. For the past 5 years, Denise has been the Associate Dean for Clinical Research for Duke University School of Medicine. In this role, she leads the Duke Office of Clinical Research (DOCR) a support office of expertise in study logistics, data management, regulatory oversight and guidance for clinical research operations for Duke as a site.
Brian C. Springer, M.H.A.
Vice President, Research Administration and Associate Center Director, Administration at Moffitt Cancer Center and Research Institute
Brian C. Springer, M.H.A joined Moffitt Cancer Center and Research Institute in September 2013 as Vice President, Research Administration and Associate Center Director, Administration. Mr. Springer is responsible for leading research development, planning, direction, finance, operation, and evaluation, as well as renewal of the National Cancer Institute core grant.
Mr. Springer has 21 years of experience coordinating and directing large research initiatives, with more than 19 years of experience in NCI cancer center administration. He has particular interests in diversity, disparities research, outreach, and education, with significant experience in developing and operating these programs. Mr. Springer developed Cancer Center Support Grant applications at Moffitt, Roswell Park Cancer Institute, Alvin J. Siteman Cancer Center (2), and Wake Forest Baptist Comprehensive Cancer Center. He has expertise in clinical research, having served as a past director of a clinical trials core, and administrator of NCI-funded clinical research grants.
Mr. Springer has served on the Cancer Center Administrators Forum (CCAF) Executive Committee, and the Steering Committee of the Association of American Cancer Institutes’ Clinical Research Initiative. He currently co-chairs the CCAF Information Technology (CCAF-IT) Steering Committee, and serves on several committees of the national Oncology Research Information Exchange Network (ORIEN). In addition, Mr. Springer has held leadership positions in the National Comprehensive Cancer Network and Alliance of Dedicated Cancer Centers. During the summer and fall of 2014, Mr. Springer served as co-chair of the National Cancer Institute Phase 2 Working Group to streamline the Cancer Center Support Grant application and review process. He currently serves on the External Advisory Boards of more than 10 Cancer Centers. He also serves as a Board Member and Secretary of the Lions Eye Institute for Transplant & Research in Tampa, FL, and as a Board Member of the 50 Hoops/National Physician & Family Referral Project in Dallas, TX.
Mr. Springer earned a Master of Healthcare Administration degree from The University of North Carolina at Chapel Hill.
Dr. Ravi Thadhani, M.D., M.P.H.
Professor of Medicine, Harvard Medical School; Chief, Division of Nephrology Massachusetts General Hospital; Executive Director, Clinical Trials Office Partners HealthCare
Dr. Ravi Thadhani, M.D., M.P.H. is a Professor of Medicine at Harvard Medical School, Chief of the Division of Nephrology at Massachusetts General Hospital, and Executive Director of the Clinical Trials Office at Partners Health Care. He received his Doctor of Medicine degree from the University of Pennsylvania in 1991, and in 1997 received his Masters in Public Health in Epidemiology from the Harvard School of Public Health.
He is a clinical and translational investigator and over the past 16 years his research laboratory has focused on understanding vitamin D metabolism and on developing diagnostics and therapeutics related to preeclampsia. In dialysis, he has examined the effect of vitamin D in the survival of chronic hemodialysis patients. These series of observational studies have included thousands of dialysis patients throughout the U.S. His studies have been confirmed by over 25 independent investigators world-wide. Clinical practices (academic and non-academic) have implemented practice patterns aligned with this work, and national and international practice guidelines have highlighted these studies. Acknowledging the observational nature of this work, however, he pursued animal models examining the cardiac effects of vitamin D with basic science collaborators. His series of human and animal experimental studies led to an investigator initiated (Thadhani, PI) multicenter multinational (> 60 centers world-wide) clinical trial in patients with kidney disease (e.g., PRIMO – Paricalcitol benefits in Renal Insufficiency associated cardiac Morbidity, clinicaltrials.gov NCT00497146). PRIMO is the first randomized trial in nephrology to test the hypothesis that active vitamin D therapy favorably affects cardiac hypertrophy and diastolic dysfunction. His team coordinated the entire study and the top-line results were published in JAMA in 2012. Several additional national and international studies including follow-up studies in the general population (e.g., VITAL) are ongoing. Concerning preeclampsia, Dr. Thadhani and his collaborators have developed novel diagnostic tests, and are now arduously working on therapies to safely prolong pregnancy in women with very severe preterm preeclampsia. He has several grants, invited speaking events, book chapters, and publications in these areas, including invited commentaries.
Dr. Thadhani has significant experience in research training and has formally supervised and trained 25 post-doctoral fellows, many of whom now occupy faculty research positions at Harvard Medical School and other institutions throughout the world and who have secured their own funding from the National Institutes of Health, the American Society of Nephrology, American Heart Association, Juvenile Diabetes Association, and the National Kidney Foundation among other sources. He serves as mentor and advisory committee member of several renal fellows, as well as several post-doctoral fellows. He established his interdisciplinary clinical research laboratory at Massachusetts General Hospital in 1999 and it consists of fellows, junior and senior faculty members, a data manager, statisticians, laboratory technicians, nurses, research study coordinators/assistants, and students (http://thadhanilab.org/). The theme of his laboratory has been on translational research and he has a strong track record of collaborating with basic scientists. The lab conducts observational studies, basic science research, and clinical trials with the goal of finding new diagnostic approaches and therapeutic interventions for patients with kidney disease and related disorders.
He has served as a reviewer for and has published in several journals including New Engl J Med, the Lancet, J Am Soc Nephrol, Kidney Int, and J Clin Endocrinol Metab. A complete list of his published work may be found at the following link:
Dr. Thadhani has been the recipient of numerous honors and awards including the 2008 American Society of Clinical Investigation, Inducted Member; the 2014 Alumni Award of Merit from the Harvard School of Public Health Alumni Association; the 2015 American Association of Physicians, Inducted Member; and the 2015 Robert W. Schrier Endowed Lectureship from The
American Society of Nephrology. In January 2016, Dr. Thadhani was the recipient of Honors for Outstanding Contributions in Nephrology Research & Education from the International Society of Nephrology & American Nephrologists of Indian Origin. His current support includes 7 grants from the NIH as well as private corporations. He is a member of the American Society of Nephrology, American Society of Clinical Investigation, National Kidney Foundation, and the
Association of American Physicians. Finally, Dr. Thadhani is a sought-after lecturer and
presenter at regional, national, and international venues on topics such as Translational Studies in CKD, Preeclampsia, and Vitamin D.